INTERMEDIATE-RISK GROUP FOR DIFFERENTIATED CARCINOMA OF THYROID

被引:0
作者
SHAHA, AR
LOREE, TR
SHAH, JP
机构
关键词
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. We have previously described prognostic factors in differentiated carcinoma of the thyroid gland relating to age, size and extrathyroid extension of the tumor, histologic grade, gender, and distant metastasis. These factors have identified patients in the low-risk group with excellent prognosis and the high-risk group with significant mortality. However, some patients fall within the intermediate-risk category where due deliberation in decision making is required for selection of appropriate treatment. Methods. A retrospective review of a consecutive series of 1038 previously untreated patients with differentiated carcinoma of thyroid treated during a period of 55 years was undertaken. data gathered from review of the charts were subjected to univariate and multivariate analysis to assess prognostic factors. On the basis of the patient's age, presence of distant metastasis, and size, grade, and histologic characteristics of the tumor they could be classified into low-, intermediate-, and high-risk categories. Thus 403 (39%) patients were in the low-risk group, 232 (22%) patients in the high-risk category, and 403 (39%) patients in the intermediate-risk category. Results. With a median follow-up of 20 years, 99% survival was achieved in the low-risk group, whereas only 57% survived in the high-risk group. Interestingly, in the intermediate-risk category of 403 patients, the 20-year survival was only 85%. Our results clearly identify a distinct intermediate-risk category that includes low-risk patients with high-risk tumor or high-risk patients with low-risk tumor. Conclusion. Patients in the intermediate-risk category should be considered for an aggressive treatment approach based on individual prognostic factors.
引用
收藏
页码:1036 / 1041
页数:6
相关论文
共 50 条
  • [41] Development of prognostic signatures for intermediate-risk papillary thyroid cancer
    Brennan, Kevin
    Holsinger, Christopher
    Dosiou, Chrysoula
    Sunwoo, John B.
    Akatsu, Haruko
    Haile, Robert
    Gevaert, Olivier
    BMC CANCER, 2016, 16
  • [42] Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
    Gao, Haiyan
    Huang, Jiyuan
    Dai, Qingjing
    Su, Juan
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2023, 67 (02): : 197 - 205
  • [43] The diagnostic value of stimulated serum thyroglobulin in the follow-up of low and intermediate-risk patients with differentiated thyroid cancer
    Mihaljevic, I.
    Wagenhofer, V.
    Kralj, T.
    Vrdoljak, D.
    Kizivat, T.
    Mudri, D.
    Franceschi, M.
    Jukic, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S699 - S700
  • [44] Response to: Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma''
    Boucai, Laura
    Wang, Laura Y.
    Smith, Andrew W.
    Palmer, Frank L.
    Mahrous, Azhar
    Tuttle, R. Michael
    Fagin, James A.
    THYROID, 2015, 25 (11) : 1269 - +
  • [45] Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients
    Cho, Jae Won
    Lee, Yu-mi
    Lee, Yi Ho
    Hong, Suck Joon
    Yoon, Jong Ho
    CLINICAL ENDOCRINOLOGY, 2018, 89 (01) : 100 - 109
  • [46] Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis
    Xu, Siyuan
    Huang, Hui
    Huang, Ying
    Qian, Jiaxin
    Wang, Xiaolei
    Xu, Zhengang
    Liu, Shaoyan
    Liu, Jie
    JAMA SURGERY, 2023, 158 (01) : 73 - 79
  • [47] Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study
    Ballal, Sanjana
    Soundararajan, Ramya
    Garg, Aayushi
    Chopra, Saurav
    Bal, Chandrasekhar
    CLINICAL ENDOCRINOLOGY, 2016, 84 (03) : 408 - 416
  • [48] Comparisons between Thyroid Hormone Withdrawal and Recombinant Human Thyroid-stimulating Hormone Administration for Radioiodine Ablation in Patients with Intermediate-risk to High-risk Differentiated Thyroid Cancer
    Iizuka, Y.
    Katagiri, T.
    Ogura, K.
    Inoue, M.
    Nakamura, K.
    Mizowaki, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S141 - S141
  • [49] Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis
    Maria Gomez-Perez, Ana
    Garcia-Aleman, Jorge
    Molina-Vega, Maria
    Sebastian Ochoa, Arantzazu
    Perez Garcia, Pilar
    Mancha Doblas, Isabel
    Tinahones, Francisco J.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (02)
  • [50] Selective Use of Radioactive Iodine in Intermediate-Risk Papillary Thyroid Cancer
    Nixon, Iain J.
    Patel, Snehal G.
    Palmer, Frank L.
    DiLorenzo, Monica M.
    Tuttle, R. Michael
    Shaha, Ashok
    Shah, Jatin P.
    Ganly, Ian
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2012, 138 (12) : 1141 - 1146